Hepatic Lipid Metabolism-Alcohol Use Disorder
Key facts
- Who runs it
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Where
- Bethesda, United StatesSee the site
- Trial code
- Status
- Recruiting
- People taking part
- 25 people, planned
- Started
- 5 Oct 2026
- Expected to end
- 30 Nov 2029
- Type of study
- Observational
- Treatments tested
- Liver biopsy
- Record updated
- 8 October 2026
Who can take part
- Age
- 18 years to 100 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (13)Hide the full registry criteria
Who cannot take part
- Existing use of cholesterol lowering medications including statins, fibrates, or other similar medications used for the purposes of treating hyperlipidemia
- Existing diagnosis of hyperlipidemia or essential hypertension
- Those with evidence of severe alcoholic hepatitis with a Maddrey s Discriminant Function > 32
- Those with other chronic liver diseases including chronic hepatitis B (positive hepatitis B surface Ag on admission), hepatitis C (positive hepatitis C RNA), or autoimmune hepatitis (clinical diagnosis based on high titer of positive ANA and or anti smooth muscle Ab and a history of autoimmune disease)
- HIV infection
- Hemoglobin A1c >= 6.5%
- Contraindication or inability to perform a liver biopsy; Participants with coagulopathy (PT/PTT values that are prolonged (Bullet) 3 seconds from the upper limit of the normal, including treatment with oral and parenteral anticoagulants), thrombocytopenia (< 70,000), abnormal bleeding time or platelet dysfunction. Antiplatelet agents taken for cardiovascular prevention will not exclude participants, unless they cannot be stopped safely for the performance of a liver biopsy; Hemoglobin level < 11 g/dL; Inability to provide informed consent
- An individual who meets any of the following criteria will be excluded from participation in this study:
- Pregnancy
- Waist to hip ratio: >=0.90 in males, >=0.85 in females
Other criteria
- INCLUSION CRITERIA:; In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- Any individual >=18 years of age who is enrolled in 14-AA-0181 and is seeking inpatient treatment
- Vibration Controlled Elastography parameters with initial CAP of >295dB/m
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Alcohol use disorder
This trial is currently available in United States.
- National Institutes of Health Clinical CenterBethesda, United StatesContact: NIH Clinical Center Office of Patient Recruitment (OPR)Taking people
About the trial
What the trial wants to find out
Patients with hepatic steatosis due to alcohol will be offered liver biopsies when they enter a detoxification program. The first biopsy will occur in the first week of admission and the second in the fourth week when the steatosis has resolved. The hepatic transcriptome will be compared,
The group in the trial
- Liver biopsy
All participants in the study will undergo liver biopsies
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Mechanisms in Hepatic Lipid Metabolism in Alcohol Use Disorder: From Genomics, Transcriptomics to Metabolomics
- Criteria questions
- Built from NCT07191561, who can take part
- Record updated
- 8 October 2026